ERBB2 and breast carcinoma: IHC scores of 1+ or 2+ breast cancer have been classified as HER2-low breast cancer [35], and ERBB2-targeted therapy (trastuzumab deruxetecan) showed prolonged survival in patients with HER2-low breast cancer [36].